Background: Multitarget stool DNA (mt-sDNA) is an increasingly utilized noninvasive option for colorectal cancer screening; however, its impact is limited by imperfect test adherence. Tailored patient navigation (TPN) improves adherence for other cancer screening tests, but its role in mt-sDNA is not known.
Aim: Determine whether TPN improves mt-sDNA completion and reduces sample could not be processed (SCNBP) result rates.
Setting: A large, urban, academic primary care clinic serving a medically vulnerable population.
Participants: All patients who received mt-sDNA order in 2022 and 2023.
Program Description: A patient navigator outreached all patients ordered mt-sDNA to support test completion during the 12-month intervention period in 2023.
Program Evaluation: Rates of mt-sDNA completion within 90 days and SCNBP results were compared between the 12-month intervention and pre-intervention periods using generalized estimating equations. A total of 2694 patients received 3297 orders during the study. TPN was significantly associated with improved rates of 90-day mt-sDNA completion (51% vs. 39%, OR 1.67, p < .001) and SCNBP results (4% vs. 5%, OR 0.55, p < .001).
Discussion: Tailored patient navigation was associated with improved rates of mt-sDNA completion and SCNBP results despite built-in navigation services provided by the manufacturer. TPN for mt-sDNA is a promising strategy for enhancing colorectal cancer screening uptake.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11606-024-09201-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of a Tailored Patient Navigation Program for Improving Multitarget Stool DNA Test Adherence.
J Gen Intern Med
November 2024
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background: Multitarget stool DNA (mt-sDNA) is an increasingly utilized noninvasive option for colorectal cancer screening; however, its impact is limited by imperfect test adherence. Tailored patient navigation (TPN) improves adherence for other cancer screening tests, but its role in mt-sDNA is not known.
Aim: Determine whether TPN improves mt-sDNA completion and reduces sample could not be processed (SCNBP) result rates.
The Utility of Multitarget Stool DNA Testing for Colorectal Cancer Screening After a Normal Colonoscopy.
J Gastrointest Cancer
October 2024
Digestive Disease Research Center, Medical University of South Carolina, Charleston, SC, USA.
Background: Multitarget stool DNA (MT-sDNA) tests (here, Cologuard®) are currently used in average-risk patients as a primary method of screening for colorectal cancer. However, MT-sDNA testing has also been used in patients who previously underwent colonoscopy who wish to avoid repeat colonoscopy. Here, in a large primary care practice setting, our aim was to evaluate the diagnostic performance of MT-sDNA testing in patients with a previously normal colonoscopy.
View Article and Find Full Text PDFPatient-Provider Communication and Colorectal Cancer Screening Completion Using Multi-target Stool DNA Testing.
J Cancer Educ
July 2024
Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Article Synopsis
- * A survey conducted with US adults aged 45-75 identified that discussing the mt-sDNA test with providers (including topics like costs and follow-up) positively influenced completion rates and future usage.
- * The study highlights the importance of patient-provider communication in CRC screening, showing that discussing the pros and cons and involving patients in decision-making can improve adherence to screening guidelines.
Recruitment strategies and consent rates in a national prospective colorectal cancer screening cohort: results from year 1 of the Voyage Study.
BMJ Open Gastroenterol
July 2024
Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Objective: To identify the optimal incentive protocol for maximising participation while managing study costs during the Voyage trial.
Design: Prospective cohort (Voyage trial) of colorectal cancer (CRC) incidence and mortality outcomes in individuals screened with multitarget stool DNA (mt-sDNA) served as the population. A subset was randomised to receive postage stamps as a pre-consent incentive, or as a post-consent incentive after completion of the consent and questionnaire.
Provider communication contributes to colorectal cancer screening intention through improving screening outcome expectancies and perceived behavioral control.
Soc Sci Med
January 2024
Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Colorectal cancer (CRC) screening continues to be underutilized in the US despite the availability of multiple effective, guideline-recommended screening options. Provider recommendation has been consistently shown to improve screening completion. Yet, available literature provides little information as to how specific information providers communicate influence patient decision-making about CRC screening.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!